ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Bristol-Myers, H3 Biomedicine explore RNA splicing drugs for cancer
December 25, 2018Bristol-Myers Squibb is tapping Eisai spinoff H3 Biomedicine and its RNA-splicing technology for a multiyear research partnership.... -
H3 Biomedicine Reports Discovery of Recurrent RNA Splicing Factor Mutations in Non-Hodgkin’s Lymphoma and Multiple Myeloma
April 18, 2018H3 Biomedicine Inc today announced novel findings from a comprehensive genomic analysis of 6,235 patients across 15 hematologic malignancies. -
FDA grants orphan drug status to H3 Biomedicine’s cancer treatment H3B-8800
August 17, 2017H3 Biomedicine, a member of Eisai’s global Oncology Business Group, has received orphan drug designation from the US Food and Drug Administration (FDA) for its H3B-8800, a clinical compound used to treat patients with acute myelogenous leukaemia (AML) and
Pharma Sources Insight January 2025
